Keeping the world in fine fettle is no easy task, but someone’s got to do it. Luckily Boehringer Ingelheim has Martin Beck as the managing director of its Human Pharma Germany business to call on as it strives to create ground-breaking medicines to improve the lives of millions of people around the world.
Boehringer Ingelheim is driven by one goal: to improve the health of humans and animals alike. Since being founded by Albert Boehringer in Germany in 1885, the pharmaceutical company has become one of the biggest in the world and continues to better countless lives with its selfless ambition. Headquartered in Ingelheim, it operates globally with 176 affiliates and has some 50,000 employees on its books. One thing that sets it apart from the industry is that it’s family-owned, so Boehringer Ingelheim has benefitted from unparalleled commitment, trust, and leadership from day one. MD Martin Beck has been part of the company’s clear vision over the last two decades – he started out as a scholarship student 17 years ago before rising to the top. Despite his impressive tenure, he looks as fresh as the day he first walked in through the door (sadly Boehringer Ingelheim hasn’t found a way to reverse aging…yet). One of Martin’s tasks is to make sure his team continues to pioneer cut- ting-edge treatments for an array of diseases and illnesses, from diabetes to stroke prevention.
“Serving mankind and improving the health of patients is at the heart of what we do here at Boehringer Ingelheim,” Martin says. “We’re 100% focused on patients and determined to improve the health of millions of people around the world. To do this we are driven by innovation and research.”
Preparing today for tomorrow
Since becoming MD at the beginning of 2019, Martin has worked tirelessly to improve an already successful strategy. He speaks of agility, accountability, and intrapreneurship fuelling creativity in medicine and engaging with customers in novel ways. Countless people rely on the medicines the company produces, which as you can probably imagine means a tonne of responsibility rests of Martin shoulders. Luckily, he’s well versed in keeping a cool head.
“We think long-term and have a plan set out. We have many clinical and pre-clinical projects in the pipeline in different therapeutic areas, like oncology and immunology, as well as cardiometabolic and respiratory diseases,” he explains. “We are driving this research further and currently looking at 90 preclinical and clinical pipeline projects. We use this term because nothing is certain in this line of research. We want to bring value through innovation – our goal is to approve 15 new drugs with an adjusted probability by 2025.”
Bringing products to market can be a real challenge in the pharma game. There are so many stages of clinical research and testing that need to be passed before a new medicine is approved by international governing bodies. To release a particular drug worldwide means meeting all of the different standards in each country, but Martin says no mountain is too tall